Holding(s) in Company TR-1: Standard form for notification of major holdings
September 09, 2019 09:33 ET
|
Verona Pharma plc
LONDON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word...
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
September 03, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma plc: PDMR Dealing
August 09, 2019 04:35 ET
|
Verona Pharma plc
LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
August 06, 2019 02:00 ET
|
Verona Pharma plc
Initiated Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator Initiated first Phase 2 study with metered-dose inhaler formulation Post-period end reported positive...
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
August 05, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data...
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
July 30, 2019 02:00 ET
|
Verona Pharma plc
LONDON, July 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces...
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
July 24, 2019 02:00 ET
|
Verona Pharma plc
LONDON, July 24, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces...
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
June 25, 2019 02:00 ET
|
Verona Pharma plc
LONDON, June 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior...
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
June 04, 2019 02:00 ET
|
Verona Pharma plc
LONDON, June 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces the initiation of a...
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
May 30, 2019 02:00 ET
|
Verona Pharma plc
LONDON, May 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces...